The American Journal of Managed Care

Bictegravir Receives Expanded Indication by FDA to Treat HIV

Patients with HIV who have suppressed viral loads and pre-existing resistance will be able to use bictegravir with this FDA approval. The FDA has approved an expanded indication for bictegravir ...
Nasdaq

Gilead Sciences : FDA Expands Biktarvy Indication For HIV Treatment

(RTTNews) - The U.S. Food and Drug Administration approved a new, expanded indication for Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat people ...
Drug Store News

Gilead’s Biktarvy receives FDA OK for expanded indication

Gilead Sciences received the Food and Drug Administration’s approval for a new, expanded indication for Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) ...
Health AffairsOpinion

Congress Must Continue To Fund HIV Prevention And Treatment

Funding for HIV care and prevention are key for continued progress, but recent cuts to federal funding for health agencies, ...
Business Wire

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Isl…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
The American Journal of Managed Care

Long-Acting Injectables in the HIV Treatment Landscape

The role of and indication for long-acting injectables is highlighted as a treatment approach for HIV. Adam C. Welch, PharmD, MBA: An evolving space is long-acting injectables. It sounds great: 1 ...

MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...
CSR Wire

Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-Daily Treatment for Children Living With HIV

PITTSBURGH and BANGALORE, India, September 6, 2023 /CSRwire/ - Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced U.S. Food and Drug Administration (FDA) tentative approval for ...
MedPage Today

Antiretroviral Therapy for HIV: When Less May Be More

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window "Medical ...

Self-reactive T cells may explain why some patients can't reach undetectable HIV levels

Despite the capability of antiretroviral drugs to suppress HIV to undetectable levels, some people living with the human ...
Nasdaq

Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries

HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), today ...